This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NamePirlindole
Accession NumberDB09244
TypeSmall Molecule
GroupsApproved
Description

Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant. It is structurally and pharmacologically related to metralindole.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International Brands
NameCompany
LifrilNot Available
PyrazidolNot Available
Brand mixturesNot Available
Categories
UNIIV39YPH45FZ
CAS number60762-57-4
WeightAverage: 226.323
Monoisotopic: 226.146998588
Chemical FormulaC15H18N2
InChI KeyIWVRVEIKCBFZNF-UHFFFAOYSA-N
InChI
InChI=1S/C15H18N2/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13/h5-6,9,13,16H,2-4,7-8H2,1H3
IUPAC Name
12-methyl-1,4-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-9(16),10,12,14-tetraene
SMILES
CC1=CC=C2N3CCNC4CCCC(=C34)C2=C1
Pharmacology
Indication

For the treatment of depression.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePirlindole may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePirlindole may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePirlindole may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePirlindole may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of Pirlindole.Experimental
AcarbosePirlindole may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPirlindole may increase the hypotensive activities of Acebutolol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
AlbiglutidePirlindole may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Pirlindole.Approved, Illicit
AliskirenPirlindole may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pirlindole.Approved, Investigational
AlogliptinPirlindole may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololPirlindole may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Pirlindole.Approved
AmbrisentanPirlindole may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptinePirlindole may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylinePirlindole may increase the serotonergic activities of Amitriptyline.Approved
AmlodipinePirlindole may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Amoxapine.Approved
AmphetaminePirlindole may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Pirlindole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Arformoterol.Approved, Investigational
AtenololPirlindole may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePirlindole may increase the central neurotoxic activities of Atomoxetine.Approved
AtropinePirlindole may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bambuterol.Approved
BenazeprilPirlindole may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePirlindole may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinPirlindole may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetaminePirlindole may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPirlindole may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Pirlindole.Approved
BetaxololPirlindole may increase the hypotensive activities of Betaxolol.Approved
BethanidinePirlindole may increase the hypotensive activities of Bethanidine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
BezafibrateThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bezafibrate.Approved
BimatoprostPirlindole may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPirlindole may increase the hypotensive activities of Bisoprolol.Approved
BosentanPirlindole may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumPirlindole may increase the hypotensive activities of Bretylium.Approved
BrimonidinePirlindole may increase the hypotensive activities of Brimonidine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Pirlindole.Approved, Investigational
BupranololPirlindole may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pirlindole.Approved, Illicit, Investigational, Vet Approved
BupropionPirlindole may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pirlindole.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirlindole.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Pirlindole.Approved
CanagliflozinPirlindole may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanPirlindole may increase the hypotensive activities of Candesartan.Approved
CandoxatrilPirlindole may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPirlindole may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pirlindole.Approved, Investigational
CaroxazonePirlindole may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololPirlindole may increase the hypotensive activities of Carteolol.Approved
CarvedilolPirlindole may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPirlindole may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazidePirlindole may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePirlindole may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamidePirlindole may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidonePirlindole may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilPirlindole may increase the hypotensive activities of Cilazapril.Approved
CirazolinePirlindole may increase the hypertensive activities of Cirazoline.Experimental
CitalopramPirlindole may increase the serotonergic activities of Citalopram.Approved
ClemastinePirlindole may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Clenbuterol.Approved, Vet Approved
ClomipraminePirlindole may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidinePirlindole may increase the hypotensive activities of Clonidine.Approved
CryptenaminePirlindole may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Pirlindole.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
CyclothiazidePirlindole may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadinePirlindole may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPirlindole may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetinePirlindole may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinPirlindole may increase the hypotensive activities of Debrisoquin.Approved
DeserpidinePirlindole may increase the hypotensive activities of Deserpidine.Approved
DesipraminePirlindole may increase the serotonergic activities of Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirlindole.Approved
DesvenlafaxinePirlindole may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidatePirlindole may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePirlindole may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPirlindole may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxidePirlindole may increase the hypotensive activities of Diazoxide.Approved
DiethylpropionPirlindole may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Pirlindole.Approved
DihydralazinePirlindole may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Pirlindole.Approved
DiltiazemPirlindole may increase the hypotensive activities of Diltiazem.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dipivefrin.Approved
DisopyramidePirlindole may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.Approved, Investigational
DomperidoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePirlindole may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPirlindole may increase the serotonergic activities of Dosulepin.Approved
DoxapramPirlindole may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPirlindole may increase the hypotensive activities of Doxazosin.Approved
DoxepinPirlindole may increase the serotonergic activities of Doxepin.Approved
DoxylaminePirlindole may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Pirlindole is combined with Droxidopa.Approved, Investigational
DulaglutidePirlindole may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePirlindole may increase the serotonergic activities of Duloxetine.Approved
EfonidipinePirlindole may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pirlindole.Approved, Investigational
EmpagliflozinPirlindole may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPirlindole may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPirlindole may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pirlindole.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Pirlindole is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrinePirlindole may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolPirlindole may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPirlindole may increase the hypotensive activities of Eprosartan.Approved
ErgotaminePirlindole may increase the hypertensive activities of Ergotamine.Approved
EscitalopramPirlindole may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapinePirlindole may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pirlindole.Approved
EtoperidonePirlindole may increase the serotonergic activities of Etoperidone.Approved
ExenatidePirlindole may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePirlindole may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamPirlindole may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Pirlindole.Approved, Illicit, Investigational, Vet Approved
FluoxetinePirlindole may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxaminePirlindole may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Formoterol.Approved, Investigational
FosinoprilPirlindole may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Pirlindole.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Pirlindole.Approved, Vet Approved
GliclazidePirlindole may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePirlindole may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePirlindole may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePirlindole may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzPirlindole may increase the hypotensive activities of Guanabenz.Approved
GuanadrelPirlindole may increase the hypotensive activities of Guanadrel.Approved
GuanethidinePirlindole may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePirlindole may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumPirlindole may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazinePirlindole may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazinePirlindole may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePirlindole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePirlindole may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydromorphone.Approved, Illicit
HydroxyamphetaminePirlindole may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
ImidaprilPirlindole may increase the hypotensive activities of Imidapril.Investigational
ImipraminePirlindole may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol.Approved
IndalpinePirlindole may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePirlindole may increase the hypotensive activities of Indapamide.Approved
IndenololPirlindole may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPirlindole may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPirlindole may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPirlindole may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePirlindole may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePirlindole may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPirlindole may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPirlindole may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozidePirlindole may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Pirlindole.Withdrawn
IrbesartanPirlindole may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Pirlindole.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isoprenaline.Approved
IsradipinePirlindole may increase the hypotensive activities of Isradipine.Approved
KetanserinPirlindole may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pirlindole.Approved, Nutraceutical, Withdrawn
LabetalolPirlindole may increase the hypotensive activities of Labetalol.Approved
LacidipinePirlindole may increase the hypotensive activities of Lacidipine.Approved
LanreotidePirlindole may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostPirlindole may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePirlindole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pirlindole.Approved
LevomilnacipranPirlindole may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinPirlindole may increase the hypertensive activities of Levonordefrin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Pirlindole is combined with Linezolid.Approved, Investigational
LiraglutidePirlindole may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePirlindole may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPirlindole may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Pirlindole.Approved
LithiumThe risk or severity of adverse effects can be increased when Pirlindole is combined with Lithium.Approved
LofexidinePirlindole may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanPirlindole may increase the hypotensive activities of Losartan.Approved
MacitentanPirlindole may increase the hypotensive activities of Macitentan.Approved
ManidipinePirlindole may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pirlindole.Approved
MebanazinePirlindole may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylaminePirlindole may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPirlindole may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedronePirlindole may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePirlindole may increase the hypertensive activities of Mephentermine.Approved
MequitazinePirlindole may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolPirlindole may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminPirlindole may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methadone.Approved
MethamphetaminePirlindole may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoxaminePirlindole may increase the hypertensive activities of Methoxamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methyldopa.Approved
Methylene bluePirlindole may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidatePirlindole may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololPirlindole may increase the hypotensive activities of Metipranolol.Approved
MetolazonePirlindole may increase the hypotensive activities of Metolazone.Approved
MetoprololPirlindole may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePirlindole may increase the hypotensive activities of Metyrosine.Approved
MianserinPirlindole may increase the neurotoxic activities of Mianserin.Approved
MibefradilPirlindole may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrinePirlindole may increase the hypertensive activities of Midodrine.Approved
MifepristonePirlindole may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPirlindole may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranPirlindole may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Pirlindole.Approved
MinoxidilPirlindole may increase the hypotensive activities of Minoxidil.Approved
MirtazapinePirlindole may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPirlindole may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Pirlindole is combined with Moclobemide.Approved
MoexiprilPirlindole may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Morphine.Approved, Investigational
MoxonidinePirlindole may increase the hypotensive activities of Moxonidine.Approved
NadololPirlindole may increase the hypotensive activities of Nadolol.Approved
NaftopidilPirlindole may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Pirlindole.Approved, Investigational
NateglinidePirlindole may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPirlindole may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePirlindole may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Pirlindole.Withdrawn
NicardipinePirlindole may increase the hypotensive activities of Nicardipine.Approved
NicorandilPirlindole may increase the hypotensive activities of Nicorandil.Approved
NiguldipinePirlindole may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePirlindole may increase the hypotensive activities of Nilvadipine.Approved
NimodipinePirlindole may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePirlindole may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePirlindole may increase the hypotensive activities of Nitrendipine.Approved
NitroprussidePirlindole may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePirlindole may increase the hypertensive activities of Norepinephrine.Approved
NortriptylinePirlindole may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinPirlindole may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotidePirlindole may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olanzapine.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Pirlindole.Experimental
OlmesartanPirlindole may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olodaterol.Approved
OmapatrilatPirlindole may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolPirlindole may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Orciprenaline.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pirlindole.Approved
OxprenololPirlindole may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pirlindole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirlindole.Approved, Vet Approved
PargylinePargyline may increase the hypertensive activities of Pirlindole.Approved
ParoxetinePirlindole may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotidePirlindole may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololPirlindole may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePirlindole may increase the hypoglycemic activities of Pentamidine.Approved
PentoliniumPirlindole may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Pirlindole.Approved, Vet Approved, Withdrawn
PerindoprilPirlindole may increase the hypotensive activities of Perindopril.Approved
PethidinePirlindole may increase the serotonergic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Pirlindole.Approved
PheniprazinePirlindole may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoxybenzaminePirlindole may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePirlindole may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhenterminePirlindole may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePirlindole may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePirlindole may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Pirlindole.Approved, Illicit
PinacidilPirlindole may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPirlindole may increase the hypotensive activities of Pindolol.Approved
PioglitazonePirlindole may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Pirbuterol.Approved
PivhydrazinePirlindole may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenPirlindole may increase the anticholinergic activities of Pizotifen.Approved
PolythiazidePirlindole may increase the hypotensive activities of Polythiazide.Approved
PramlintidePirlindole may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinPirlindole may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Procaterol.Approved
PropranololPirlindole may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylinePirlindole may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Pirlindole.Investigational
PseudoephedrinePirlindole may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilPirlindole may increase the hypotensive activities of Quinapril.Approved, Investigational
QuininePirlindole may increase the hypoglycemic activities of Quinine.Approved
RamiprilPirlindole may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Pirlindole.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Pirlindole.Approved
RemikirenPirlindole may increase the hypotensive activities of Remikiren.Approved
RepaglinidePirlindole may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePirlindole may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Reserpine.Approved
RilmenidinePirlindole may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPirlindole may increase the hypotensive activities of Riociguat.Approved
RitobegronPirlindole may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Pirlindole.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Pirlindole.Approved, Investigational
RosiglitazonePirlindole may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazinePirlindole may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salmeterol.Approved
SaprisartanPirlindole may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPirlindole may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Pirlindole.Approved, Investigational, Vet Approved
SelexipagPirlindole may increase the hypotensive activities of Selexipag.Approved
SertralinePirlindole may increase the serotonergic activities of Sertraline.Approved
SitagliptinPirlindole may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPirlindole may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilPirlindole may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Pirlindole.Approved, Investigational
SulfadiazinePirlindole may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePirlindole may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePirlindole may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Pirlindole.Approved, Investigational
SunitinibPirlindole may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pirlindole.Approved
TelmisartanPirlindole may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPirlindole may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline.Approved
TerlipressinPirlindole may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Pirlindole.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pirlindole.Approved
TetryzolinePirlindole may increase the hypertensive activities of Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Pirlindole.Approved
TibolonePirlindole may increase the hypotensive activities of Tibolone.Approved
TicrynafenPirlindole may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololPirlindole may increase the hypotensive activities of Timolol.Approved
TolazamidePirlindole may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePirlindole may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePirlindole may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pirlindole.Approved, Withdrawn
ToloxatonePirlindole may increase the hypertensive activities of Toloxatone.Approved
TorasemidePirlindole may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Pirlindole.Approved, Investigational
TrandolaprilPirlindole may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Pirlindole.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Pirlindole.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
TravoprostPirlindole may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Trazodone.Approved, Investigational
TreprostinilPirlindole may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazidePirlindole may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPirlindole may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPirlindole may increase the hypotensive activities of Trimethaphan.Approved
TrimipraminePirlindole may increase the serotonergic activities of Trimipramine.Approved
UnoprostonePirlindole may increase the hypotensive activities of Unoprostone.Approved
ValsartanPirlindole may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxinePirlindole may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Pirlindole.Approved
VinpocetinePirlindole may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pirlindole.Approved
XylometazolinePirlindole may increase the hypotensive activities of Xylometazoline.Approved
ZimelidinePirlindole may increase the serotonergic activities of Zimelidine.Withdrawn
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Pirlindole.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.107 mg/mLALOGPS
logP2.1ALOGPS
logP3.1ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area16.96 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity70.42 m3·mol-1ChemAxon
Polarizability27.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIndoles and derivatives
Sub ClassCarbazoles
Direct ParentCarbazoles
Alternative Parents3-alkylindoles / Aralkylamines / Benzenoids / Pyrroles / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Hydrocarbon derivatives
SubstituentsCarbazole / 3-alkylindole / Indole / Aralkylamine / Benzenoid / Heteroaromatic compound / Pyrrole / Azacycle / Secondary amine / Secondary aliphatic amine
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Drug created on October 23, 2015 16:13 / Updated on September 01, 2017 12:04